<DOC>
	<DOCNO>NCT03094195</DOCNO>
	<brief_summary>To characterize dose response , evaluate safety efficacy three different dos EMA401 compare placebo patient post-herpetic neuralgia ( PHN )</brief_summary>
	<brief_title>Dose Response Study EMA401 Patients With Post-herpetic Neuralgia ( PHN )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>At time Screening , document diagnosis PHN ( ICD10 code B02.29 ) , define pain region rash persist 6 month onset herpes zoster rash . Be assess suffer moderate severe neuropathic pain across Screening epoch ( NRS ≥ 4 ) . Patients must document past and/or ongoing inadequate treatment response ( insufficient pain relief treatment inability tolerate ) least 2 different prescribe therapy commonly use treat consider effective Investigator treatment PHN . History current diagnosis electrocardiogram ( ECG ) abnormalities indicate significant risk safety patient participate study Major depressive episode within 6 month prior Screening and/or history diagnose recurrent major depressive disorder accord Diagnostic Statistical Manual Mental Disorders , 5th Edition ( DSMV ) diagnostic criterion Women childbearing potential , defined woman physiologically capable become pregnant . Have evidence significant renal insufficiency preexist liver condition Have platelet ≤ 100 x 10^9/L , neutrophil count &lt; 1.2 x 10^9/L ( equivalent ) , hemoglobin ≤ 100 g/L woman hemoglobin ≤ 110 g/L men . Patients know diagnosis diabetes stable medication hemoglobin A1c &gt; 8 % . Those know diagnosis diabetes hemoglobin A1c &gt; 7 % . Have previously receive herpes zoster vaccine Patient unwilling unable complete daily eDiary Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>post-herpetic neuralgia</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>angiotensin II type 2 receptor antagonist</keyword>
	<keyword>dose range</keyword>
</DOC>